If you have taken Elmiron and noticed changes in your vision—such as blurriness, difficulty reading, or dark spots—you may be wondering what symptoms to document. The medical community has long emphasized the importance of patient-reported outcomes in identifying medication side effects. This page provides a checklist of eye symptoms to record for your medical records in North Carolina.
Elmiron (pentosan polysulfate sodium) is a medication approved for the relief of bladder pain or discomfort associated with interstitial cystitis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). However, long-term use has been linked to pigmentary maculopathy, a condition characterized by pigmentary changes in the retina. The FDA-approved labeling for Elmiron includes a warning that pigmentary changes in the retina, reported in the literature as pigmentary maculopathy, have been identified with long-term use of the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Although most cases occurred after three years of use or longer, cases have been seen with a shorter duration of use. Cumulative dose appears to be a risk factor, and the visual consequences of these pigmentary changes are not fully characterized (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Visual symptoms reported in cases include difficulty reading, slow adjustment to low or reduced light environments, and blurred vision (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The clinical presentation of pigmentary maculopathy involves retinal pigment changes that may be detected through ophthalmologic examination. The labeling recommends that a detailed ophthalmologic history be obtained in all patients prior to starting treatment with Elmiron (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). For patients with pre-existing ophthalmologic conditions, a comprehensive baseline retinal examination, including color fundoscopic photography, ocular coherence tomography (OCT), and auto-fluorescence imaging, is recommended before starting therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). A baseline retinal examination, including OCT and auto-fluorescence imaging, is suggested for all patients within six months of initiating treatment and periodically while continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). If pigmentary changes in the retina develop, the risks and benefits of continuing treatment should be re-evaluated, since these changes may be irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593).
The mechanistic pathways linking Elmiron to pigmentary maculopathy are not fully understood, but the labeling notes that the etiology is unclear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The drug's pharmacology involves pentosan polysulfate sodium, which is a semi-synthetic polysaccharide. The adverse effects reported in clinical trials included deaths in 6 out of 2627 patients (0.2%) who received the drug over a period of 3 to 75 months, though these deaths appeared to be related to other concurrent illnesses or procedures, except in one patient for whom the cause was not known (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Serious adverse events occurred in 33 out of 2627 patients (1.3%), with two patients experiencing severe abdominal pain or diarrhea and dehydration requiring hospitalization (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). FDA adverse-event reports from the FAERS database provide additional evidence of the association between Elmiron and pigmentary maculopathy. The most frequently reported adverse events associated with Elmiron include maculopathy (1382 reports), off-label use (1361 reports), retinal pigmentation (607 reports), dry age-related macular degeneration (560 reports), and pigmentary maculopathy (442 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). Other reported events include visual impairment (150 reports), retinal dystrophy (141 reports), and neovascular age-related macular degeneration (141 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). These data underscore the significant number of patients who have experienced retinal changes potentially linked to Elmiron use.
For patients in North Carolina who have developed pigmentary maculopathy after using Elmiron, the statute of limitations is a critical consideration. The statute of limitations for product liability claims, including those related to inadequate warnings, varies by state. In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. Given that pigmentary maculopathy may develop after long-term use, often after three years or more, the timeline between exposure and documented harm is important. The labeling indicates that most cases occurred after three years of use or longer, but cases have been seen with a shorter duration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). This means that patients may not become aware of the injury until years after starting the medication, which could affect the start of the statute of limitations period. Settlement-related considerations for affected patients include the adequacy of warnings regarding Elmiron and pigmentary maculopathy. The FDA-approved labeling includes warnings about retinal pigmentary changes, but the labeling also states that caution should be used in patients with retinal pigment changes from other causes, as examination findings may confound the appropriate diagnosis, follow-up, and treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Patients who were not adequately warned about the risk of pigmentary maculopathy may have a basis for a claim. The large number of adverse-event reports, including 1382 reports of maculopathy and 442 reports of pigmentary maculopathy, suggests that many patients have been affected (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). However, the labeling does not provide specific guidance on the statute of limitations, and patients should consult with a legal professional to understand their rights in North Carolina.
In summary, Elmiron use is associated with pigmentary maculopathy, a condition that can cause visual symptoms such as difficulty reading and blurred vision. The risk appears to increase with cumulative dose and longer duration of use, though cases have occurred with shorter use. Patients in North Carolina who have developed this condition should be aware of the statute of limitations for filing a claim, which is generally three years from discovery of the injury. The adequacy of warnings and the timeline between exposure and harm are key factors in settlement considerations. References: (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON)
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In North Carolina, the statute of limitations for personal injury claims, including product liability claims related to Elmiron, is generally three years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. Because pigmentary maculopathy may develop after long-term use, patients should consult with a legal professional to determine the applicable deadline based on their individual circumstances.
The FDA-approved labeling for Elmiron includes a warning about pigmentary changes in the retina associated with long-term use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Additionally, FDA adverse-event reports from the FAERS database show thousands of reports of maculopathy and pigmentary maculopathy among Elmiron users (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.